Parkinson s disease and dopamine transporter neuroimaging: a critical review

Optimizing idiopathic Parkinson’s disease treatment is a challenging, multifaceted and continuous process with direct impact on patients’ quality of life. The basic tenet of this

Drug-naive patients with Parkinson’s disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [ 123 I]ß-CIT SPECT. J

a) What relationships emerge between phonological segmentation and letter knowledge and the ability to read and write in Catalan, with 5 year olds? We expected that all

Three design parameters, including the injection activity, uptake duration, and acquisition time per projection, were considered with three various levels of each for

Based on the predicted penetrance and the frequencies, a variant in PLXNA4 proved to be the best candidate and PLXNA4 was screened for additional variants in 862 PD cases and

Healthy control with mixed affinity binder (HC-MAB) and Parkinson ’ s disease with MAB (PD-MAB) groups as well as healthy control with high affinity binder (HC-HAB) and Parkinson ’

(2017) in an example within research that works with the particularity of the Anthropocene, in an attempt to understand, in a long historical perspective, the processes of formation

For the most part, available evidence from SPECT and PET studies of dopamine neuron ter- minal markers in ephedron addicts and in liver disease patients have confirmed the lack of